1. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk by Hong Zhang, Ester C. Löwenberg, Jeffrey R. Crosby, A. Robert MacLeod, Chenguang Zhao, Dacao Gao, Chris Black, Alexey S. Revenko, Joost C. M. Meijers, Erik S. Stroes, Marcel Levi, and Brett P. Monia Blood Volume 116(22):4684-4692 November 25, 2010 ©2010 by American Society of Hematology

2. Effect of FXI ASO treatment on hepatic FXI mRNA levels, FXI enzymatic activity, and aPTT ratio in mice. Hong Zhang et al. Blood 2010;116:4684-4692 ©2010 by American Society of Hematology

3. Effect of FXI ASO, warfarin, or Levonox therapy on thrombosis and bleeding in mice. Hong Zhang et al. Blood 2010;116:4684-4692 ©2010 by American Society of Hematology

4. Antithrombotic effect of FXI ASO treatment in mouse models of FeCl3-induced mesenteric vein thrombosis and stenosis-induced IVC thrombosis. Hong Zhang et al. Blood 2010;116:4684-4692 ©2010 by American Society of Hematology

5. Effects of anticoagulant treatment on bleeding in a mouse hepatectomy surgical bleeding model. Hong Zhang et al. Blood 2010;116:4684-4692 ©2010 by American Society of Hematology

6. Effect of FXI antisense treatment alone or in combination with Lovenox on thrombosis and bleeding in mice. Hong Zhang et al. Blood 2010;116:4684-4692 ©2010 by American Society of Hematology

7. Antithrombotic activity and bleeding evaluation of FXI ASO alone or in combination with clopidogrel in an aortic arterial thrombosis model. Hong Zhang et al. Blood 2010;116:4684-4692 ©2010 by American Society of Hematology